Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp4 | Acromegaly | ECE2018

Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of somatostatin analogues and pegvisomant (PAPE study): a prospective, open-label 48 week study

Coopmans Eva C , Muhammad Ammar , Janssen Joseph AMJL , van der Lely Aart J , Neggers Sebastian JCMM

Background: In the core phase of the PAPE study until 24 weeks we have shown that switching to pasireotide LAR (PAS-LAR) in well-controlled acromegaly patients receiving combination therapy of somatostatin analogues and pegvisomant (PEGV), normalizes IGF1 levels in the majority of patients. PAS-LAR induced a significant PEGV sparing effect, but this was at the expense of a higher incidence of diabetes. This extension study until 48-weeks assesses the efficacy, safety and quali...

ea0063gp117 | Calcium and Bone 2 | ECE2019

Bone health and final height in craniopharyngioma patients.

Santen Selveta S. van , Hammarstrand Casper , Olsson Daniel S. , Wijnen Mark , Johannsson Gudmundur , Lelij Aart J van der , Heuvel-Eibrink Marry M. van den , Neggers Sebastian JCMM

Introduction: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with excess mortality, obesity and endocrinopathies. These endocrinopathies may influence bone health, and increase the risk of fractures.Methods: In this retrospective study, Dutch/Swedish patients with CP were included if data was available on final height (at age >18 years) or DXA-scan results. Information from the first and last DXA-scans we...

ea0067o40 | Oral Presentations | EYES2019

T2-signal intensity, SST receptor expression and first-generation somatostatin analogs efficacy predict hormone and tumor responses to pasireotide in acromegaly

Coopmans Eva C , Schneiders Joppe J , El-Sayed Nour , Erler Nicole S , Hofland Leo J , Petrossians Patrick , van den Berg Sjoerd , van der Lely Aart-Jan , Muhammad Ammar , Neggers Sebastian JCMM

Objective: MRI T2-signal intensity and somatostatin (SST) receptor expression are recognized predictors of therapy response in acromegaly. We investigate the relationship between these predictors and the hormonal and tumor responses to PAS-LAR therapy, and compare to first-generation somatostatin receptor ligands (SRLs) responsiveness.Methods: We included 45 acromegalics initially receiving SRLs, followed by a combination therapy including pegvisomant (P...